Acme is a leading provider of contract manufacturing and development services for oral solid and sterile dosage forms in the pharmaceutical industry.

Established in 2005, Acme has evolved into a trusted partner and complete solution provider. Over the years, we have expanded into niche segments such as oral hormones—including both sex hormones and levothyroxine—as well as general injectables, including liquid and lyophilized formulations. Our operations are supported by three state-of-the-art manufacturing facilities.

Today, Acme employs over 2,500 highly skilled professionals across its facilities in Northern India. These facilities span approximately 500,000 sq. ft. and have a robust production capacity of 15 billion tablets, 5 billion capsules, and 42 million ampoules/vials annually.

Over the past decade, Acme has been audited and approved by various international regulatory agencies. Our certifications include approvals from USFDA, UK-MHRA, EU-GMP (Hungary), ANVISA (Brazil), PICS (Ukraine), INVIMA (Colombia), WHO-Geneva, and TFDA (Taiwan). We are also recognized by authorities in Nigeria (NAFDAC), Ghana (FDA), Uganda (NDA), Kenya (PPB), Nepal (DDA), Cambodia (DDF), and several other countries, including the Philippines, Vietnam, Niger, Senegal, and Sierra Leone.

As we continue our journey, Acme remains dedicated to building a sustainable future. Our commitment to quality, innovation, and regulatory excellence ensures that we deliver high-quality pharmaceutical solutions to global markets.